Literature DB >> 21900036

Combination therapies for combating antimicrobial resistance.

Michael A Fischbach1.   

Abstract

New drug development strategies are needed to combat antimicrobial resistance. The object of this perspective is to highlight one such strategy: treating infections with sets of drugs rather than individual drugs. We will highlight three categories of combination therapy: those that inhibit targets in different pathways; those that inhibit distinct nodes in the same pathway; and those that inhibit the very same target in different ways. We will then consider examples of naturally occurring combination therapies produced by micro-organisms, and conclude by discussing key opportunities and challenges for making more widespread use of drug combinations.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21900036      PMCID: PMC3196371          DOI: 10.1016/j.mib.2011.08.003

Source DB:  PubMed          Journal:  Curr Opin Microbiol        ISSN: 1369-5274            Impact factor:   7.934


  50 in total

Review 1.  Glycopeptide and lipoglycopeptide antibiotics.

Authors:  Dan Kahne; Catherine Leimkuhler; Wei Lu; Christopher Walsh
Journal:  Chem Rev       Date:  2005-02       Impact factor: 60.622

2.  An alternative bactericidal mechanism of action for lantibiotic peptides that target lipid II.

Authors:  Hester E Hasper; Naomi E Kramer; James L Smith; J D Hillman; Cherian Zachariah; Oscar P Kuipers; Ben de Kruijff; Eefjan Breukink
Journal:  Science       Date:  2006-09-15       Impact factor: 47.728

3.  Combination drugs, an emerging option for antibacterial therapy.

Authors:  Guillaume Cottarel; Jamey Wierzbowski
Journal:  Trends Biotechnol       Date:  2007-11-08       Impact factor: 19.536

Review 4.  Challenges in tuberculosis drug research and development.

Authors:  Ann M Ginsberg; Melvin Spigelman
Journal:  Nat Med       Date:  2007-03       Impact factor: 53.440

5.  Sch 40832: a novel thiostrepton from Micromonospora carbonacea.

Authors:  M S Puar; T M Chan; V Hegde; M Patel; P Bartner; K J Ng; B N Pramanik; R D MacFarlane
Journal:  J Antibiot (Tokyo)       Date:  1998-02       Impact factor: 2.649

Review 6.  HIV chemotherapy.

Authors:  D D Richman
Journal:  Nature       Date:  2001-04-19       Impact factor: 49.962

7.  Structures of MLSBK antibiotics bound to mutated large ribosomal subunits provide a structural explanation for resistance.

Authors:  Daqi Tu; Gregor Blaha; Peter B Moore; Thomas A Steitz
Journal:  Cell       Date:  2005-04-22       Impact factor: 41.582

Review 8.  Clinical role of beta-lactam/beta-lactamase inhibitor combinations.

Authors:  Nelson Lee; Kwok-Yung Yuen; Cyrus R Kumana
Journal:  Drugs       Date:  2003       Impact factor: 9.546

9.  The biosynthetic genes for clavulanic acid and cephamycin production occur as a 'super-cluster' in three Streptomyces.

Authors:  J M Ward; J E Hodgson
Journal:  FEMS Microbiol Lett       Date:  1993-06-15       Impact factor: 2.742

10.  Chemical decay of an antibiotic inverts selection for resistance.

Authors:  Adam C Palmer; Elaine Angelino; Roy Kishony
Journal:  Nat Chem Biol       Date:  2010-01-10       Impact factor: 15.040

View more
  70 in total

1.  β-Lactam Antibiotics with a High Affinity for PBP2 Act Synergistically with the FtsZ-Targeting Agent TXA707 against Methicillin-Resistant Staphylococcus aureus.

Authors:  Edgar Ferrer-González; Malvika Kaul; Ajit K Parhi; Edmond J LaVoie; Daniel S Pilch
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

2.  Combining the FtsZ-Targeting Prodrug TXA709 and the Cephalosporin Cefdinir Confers Synergy and Reduces the Frequency of Resistance in Methicillin-Resistant Staphylococcus aureus.

Authors:  Malvika Kaul; Lilly Mark; Ajit K Parhi; Edmond J LaVoie; Daniel S Pilch
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

3.  Atovaquone and ELQ-300 Combination Therapy as a Novel Dual-Site Cytochrome bc1 Inhibition Strategy for Malaria.

Authors:  Allison M Stickles; Martin J Smilkstein; Joanne M Morrisey; Yuexin Li; Isaac P Forquer; Jane X Kelly; Sovitj Pou; Rolf W Winter; Aaron Nilsen; Akhil B Vaidya; Michael K Riscoe
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

Review 4.  Evolutionary consequences of drug resistance: shared principles across diverse targets and organisms.

Authors:  Diarmaid Hughes; Dan I Andersson
Journal:  Nat Rev Genet       Date:  2015-07-07       Impact factor: 53.242

Review 5.  Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges.

Authors:  Darren Wong; Travis B Nielsen; Robert A Bonomo; Paul Pantapalangkoor; Brian Luna; Brad Spellberg
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

Review 6.  Burden of antibiotic resistance in common infectious diseases: role of antibiotic combination therapy.

Authors:  Kishor C Mehta; Ramesh R Dargad; Dhammraj M Borade; Onkar C Swami
Journal:  J Clin Diagn Res       Date:  2014-06-20

7.  Development of a Broad-Spectrum Antimicrobial Combination for the Treatment of Staphylococcus aureus and Pseudomonas aeruginosa Corneal Infections.

Authors:  Michaelle Chojnacki; Alesa Philbrick; Benjamin Wucher; Jordan N Reed; Andrew Tomaras; Paul M Dunman; Rachel A F Wozniak
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

Review 8.  Collective antibiotic resistance: mechanisms and implications.

Authors:  Nicole M Vega; Jeff Gore
Journal:  Curr Opin Microbiol       Date:  2014-09-29       Impact factor: 7.934

Review 9.  Nitric Oxide-Releasing Macromolecular Scaffolds for Antibacterial Applications.

Authors:  Lei Yang; Evan S Feura; Mona Jasmine R Ahonen; Mark H Schoenfisch
Journal:  Adv Healthc Mater       Date:  2018-05-14       Impact factor: 9.933

Review 10.  Combination approaches to combat multidrug-resistant bacteria.

Authors:  Roberta J Worthington; Christian Melander
Journal:  Trends Biotechnol       Date:  2013-01-18       Impact factor: 19.536

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.